| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8744949 | Clinical Microbiology and Infection | 2018 | 11 Pages |
Abstract
Prevention measures should be implemented to reduce the risk of latent tuberculosis or HBV reactivation among individuals receiving anti-TNF-α therapy.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Microbiology
![ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-α agents)](/preview/png/8744949.png "First Page Preview: ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-α agents)")
Authors
J.W. Baddley, F. Cantini, D. Goletti, J.J. Gómez-Reino, E. Mylonakis, R. San-Juan, M. Fernández-Ruiz, J. Torre-Cisneros,